TG Therapeutics Raises Guidance on BRIUMVI Momentum

Forward-Looking Analysis

TG Therapeutics is expected to report strong financial performance for the second quarter of 2026, driven primarily by the continued commercial success of its multiple sclerosis treatment, BRIUMVI. Based on the company's guidance raised in the first quarter, analysts project total global revenue to approach $250 million for Q2, supporting the full-year 2026 total global revenue target of approximately $925 million. Specifically, BRIUMVI U.S. net revenue is forecast to remain robust, building on the $195 million reported in Q1. While specific EPS estimates for Q2 2026 are not explicitly detailed in the provided data, the first quarter showed an EPS of $0.18 against an estimate of $0.27. However, given the raised revenue guidance and positive clinical trial data, earnings momentum is anticipated to improve. Analyst sentiment remains predominantly positive, with 88% of ratings classified as Buy, reflecting confidence in the company's growth trajectory. Price targets and specific bank predictions for Q2 are not provided in the current data set, but the consensus suggests optimism surrounding the drug's market penetration and pipeline advancements.

Historical Performance Review

In the first quarter of 2026, TG Therapeutics demonstrated strong operational execution, reporting total global revenue of $204.92 million. The company achieved a net income of $19.78 million, underpinned by a gross profit of $171.41 million. Although the reported EPS of $0.14 was lower than some expectations, the underlying revenue strength highlighted the commercial viability of BRIUMVI. These results established a solid foundation for the subsequent quarters, indicating effective cost management and high demand for the company's flagship product.

Additional News

TG Therapeutics has advanced its clinical pipeline significantly in mid-2026. On July 6, 2026, the company announced the initiation of a Phase 2 trial evaluating BRIUMVI in patients with treatment-resistant schizophrenia, leveraging emerging evidence on immune dysfunction. Prior to this, in June, positive topline Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis was reported, with 82% of subjects achieving meaningful clinical improvement. This led to the initiation of a registration-directed Phase 2 trial. Additionally, positive pharmacokinetic data supported a quarterly subcutaneous dosing regimen currently in a Phase 3 trial, with top-line data expected by year-end 2026 or early 2027. On May 27, the Phase 3 ENHANCE trial met its primary endpoint, demonstrating bioequivalence between the current Day 1/15 dosing and a new single infusion on Day 1. Furthermore, post-hoc data from Phase 3 ULTIMATE I & II trials published in June highlighted significant reductions in annualized relapse rates and improvements in disability outcomes for treatment-naïve MS patients. CEO Michael S. Weiss also participated in major investor conferences, including the Jefferies Global Healthcare Conference in May and the Goldman Sachs Healthcare Conference in June.

Summary & Outlook

TG Therapeutics exhibits robust financial health, characterized by strong revenue growth and high gross margins driven by BRIUMVI. The primary growth catalyst is the expanding commercial adoption of BRIUMVI in MS and the potential expansion into new indications like schizophrenia and myasthenia gravis. Risks include clinical trial outcomes and competition in the autoimmune space. However, the consistent raising of revenue guidance and positive Phase 3 data suggest a bullish outlook. The company is well-positioned for sustained growth, with upcoming top-line data from the subcutaneous formulation and new trial initiations likely to further validate its pipeline. Investors should anticipate continued upside potential as clinical milestones are met and revenue targets are achieved.